Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Businessweek Archives

Tom Mc Killop, Astra Zeneca

The Top 25 Managers -- Managers to Watch

Tom McKillop, AstraZeneca

When Sweden's Astra merged with Britain's Zeneca in April, 1999, to create the world's No. 5 drugmaker (AZN), some critics wondered whether newly appointed CEO Tom McKillop was up to the task. After all, the 30-year Zeneca veteran, a chemist with a PhD, had never run a big corporation. In fact, while growing up in Glasgow, the miner's son never figured he would become a businessman. But he has surprised the doubters--and himself.

McKillop, 57, who says he functions on just four hours of sleep, completed the new company's integration in a whirlwind 80 days. While other drug megamergers--such as Britain's Glaxo-SmithKline--are still works in progress, AstraZeneca PLC is already realizing big savings from its merger. It helped that McKillop, who prides himself on being a plainspoken, no-nonsense, hands-on manager, found few turf battles. He even managed a public spin-off of the company's agrochemical business in conjunction with rival Novartis (NVS).

McKillop has big hopes for such new products as schizophrenia drug Seroquel and prostate-cancer treatment Casodex. Generic versions of the company's blockbuster ulcer treatment Prilosec will be available in 2001. "You have to reinvent the business every decade," he says. This is one scientist who is not stuck in the ivory tower.Return to top


Key Accomplishments

-- Successfully spun off agrochemicals business to focus on high-margin pharmaceuticals

-- Realized merger-related savings of $600 million in 2000Return to top

blog comments powered by Disqus